TDMS Study 88127-06 Pathology Tables
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
Final#2
Facility: Battelle Columbus Laboratory
Chemical CAS #: 3524-68-3
Lock Date: 06/16/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Natural Death 2 3 3 2 3
Moribund Sacrifice 1 1 3
Survivors
Terminal Sacrifice 12 14 12 12 13 9
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (15) (15)
Hematopoietic Cell Proliferation 1 [1.0] 1 [2.0] 6 [1.5]
Infiltration Cellular 3 [1.7] 2 [1.5]
Inflammation, Chronic Active 12 [1.0] 14 [1.0] 11 [1.0] 14 [1.0] 13 [1.2] 11 [1.2]
Necrosis 1 [1.0]
Pigmentation 11 [1.0] 11 [1.0] 9 [1.0] 13 [1.0] 5 [1.0] 2 [1.0]
Bile Duct, Hyperplasia 1 [2.0]
Hepatocyte, Necrosis 2 [1.0] 2 [1.0] 2 [1.0] 3 [1.0] 4 [1.0] 2 [1.5]
Stomach, Forestomach (15) (15) (15) (15) (15) (15)
Hyperkeratosis 1 [2.0] 3 [2.0] 3 [2.0] 4 [2.0] 4 [1.8]
Inflammation 2 [2.0]
Epithelium, Hyperplasia 1 [2.0] 2 [3.0]
Epithelium, Ulcer 1 [2.0]
Tooth (4) (3) (3) (1)
Inflammation, Chronic Active 1 [4.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15) (15)
Infiltration Cellular 1 [1.0]
Inflammation, Chronic Active 1 [1.0] 1 [1.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (15) (15) (15) (15) (15) (15)
Hematopoietic Cell Proliferation 1 [1.0]
Necrosis 1 [1.0]
Capsule, Hyperplasia 1 [2.0] 4 [1.0] 7 [1.0] 2 [1.0] 1 [1.0] 2 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Pituitary Gland (15) (15) (14) (15) (15) (15)
Pars Distalis, Cyst 3 [1.0] 2 [1.0] 2 [1.0] 4 [1.0] 2 [1.0]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (15) (15) (15) (15) (15) (15)
Cyst 1 [2.0] 1 [2.0] 2 [2.0]
Uterus (15) (15) (15) (15) (15) (15)
Hydrometra 1 [2.0] 2 [2.0]
Endometrium, Hyperplasia, Cystic 11 [1.5] 9 [1.7] 7 [1.9] 10 [1.9] 11 [1.5] 7 [1.9]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (15) (14) (13) (12) (15) (14)
Hematopoietic Cell Proliferation 2 [1.0]
Inguinal, Hematopoietic Cell Proliferation 1 [1.0]
Inguinal, Hyperplasia 1 [2.0]
Inguinal, Infiltration Cellular 1 [2.0]
Inguinal, Infiltration Cellular, Plasma Cell 1 [2.0]
Mediastinal, Hematopoietic Cell Proliferation 1 [2.0]
Mediastinal, Hyperplasia 1 [2.0]
Mediastinal, Infiltration Cellular 3 [1.3] 1 [3.0]
Mediastinal, Infiltration Cellular, Plasma
Cell 1 [3.0]
Mediastinal, Necrosis, Lymphoid 1 [1.0]
Lymph Node, Mandibular (15) (15) (15) (15) (15) (13)
Hematopoietic Cell Proliferation 1 [2.0] 8 [1.8]
Hyperplasia 3 [2.0] 1 [4.0] 5 [2.4] 3 [2.0] 1 [2.0]
Infiltration Cellular 1 [2.0] 2 [2.5] 2 [2.5]
Infiltration Cellular, Plasma Cell 1 [3.0] 1 [3.0]
Necrosis, Lymphoid 1 [2.0] 1 [1.0]
Lymph Node, Mesenteric (14) (15) (15) (14) (15) (15)
Infiltration Cellular 4 [1.8]
Necrosis, Lymphoid 1 [3.0]
Spleen (15) (15) (15) (15) (15) (15)
Depletion Cellular 2 [2.0] 1 [3.0] 2 [2.5] 1 [3.0] 2 [2.5] 3 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Hematopoietic Cell Proliferation 2 [2.0] 11 [2.2] 11 [2.5]
Infiltration Cellular 1 [1.0] 1 [2.0]
Necrosis, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0]
Thymus (15) (15) (15) (14) (14) (15)
Atrophy 3 [3.3] 2 [2.5] 2 [3.0] 3 [3.0] 6 [2.7]
Pigmentation 1 [2.0]
Thymocyte, Necrosis 1 [4.0] 2 [3.5] 2 [2.0] 5 [2.4]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15) (15)
Epidermis, Skin, Site of Application,
Hyperplasia 5 [1.2] 14 [2.0] 14 [2.4] 14 [2.9]
Epidermis, Skin, Site of Application, Ulcer 1 [2.0]
Sebaceous Gland, Skin, Site of Application,
Hyperplasia, Adenomatous 1 [2.0]
Skin, Site of Application, Cyst Epithelial
Inclusion 1 1
Skin, Site of Application, Hyperkeratosis 1 [2.0] 4 [1.5] 14 [1.6] 11 [1.5] 13 [2.0]
Skin, Site of Application, Inflammation,
Chronic Active 1 [1.0] 9 [1.1] 10 [1.7] 15 [1.5]
Subcutaneous Tissue, Hemorrhage 1 [4.0]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15) (15)
Infiltration Cellular 1 [2.0]
Infiltration Cellular, Mononuclear Cell 1 [2.0]
Inflammation, Chronic Active 1 [1.0] 1 [1.0]
Alveolar Epithelium, Hyperplasia 1 [2.0]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 1 [1.0] 2 [1.5] 1 [3.0] 1 [3.0] 1 [1.0] 1 [1.0]
Nephropathy 3 [1.0] 2 [1.0]
Polyarteritis 1 [3.0]
Cortex, Cyst 2 [1.5]
Papilla, Necrosis 1 [4.0]
Renal Tubule, Degeneration 1 [2.0]
Renal Tubule, Hyperplasia 1 [1.0] 1 [4.0]
Renal Tubule, Necrosis 2 [2.0]
Renal Tubule, Regeneration 1 [1.0] 1 [1.0] 2 [1.0] 1 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 15 15 15 15 15 15
Early Deaths
Natural Death 3 2 5
Moribund Sacrifice 1 1
Survivors
Terminal Sacrifice 12 14 15 15 12 10
Animals Examined Microscopically 15 15 15 15 15 15
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Liver (15) (15) (15) (15) (15) (15)
Atrophy 1 [4.0]
Hematopoietic Cell Proliferation 2 [1.5]
Infiltration Cellular 5 [1.2] 3 [1.3]
Inflammation, Chronic Active 5 [1.0] 11 [1.0] 10 [1.0] 13 [1.0] 13 [1.1] 5 [1.0]
Mineralization 1 [2.0]
Myelodysplasia 5 [2.6]
Pigmentation 1 [1.0] 1 [1.0]
Hepatocyte, Necrosis 1 [1.0] 1 [1.0] 1 [1.0] 1 [1.0]
Hepatocyte, Vacuolization Cytoplasmic 1 [2.0]
Salivary Glands (1) (1) (1) (2)
Parotid Gland, Infiltration Cellular 1 [2.0]
Stomach, Forestomach (15) (15) (15) (15) (15) (15)
Hyperkeratosis 2 [2.0] 1 [2.0] 3 [2.0] 4 [2.0]
Epithelium, Hyperplasia 1 [2.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (15) (15) (15) (15) (15) (15)
Infiltration Cellular 3 [1.3]
Inflammation, Chronic Active 3 [1.0] 1 [1.0]
Myelodysplasia 3 [1.3]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (15) (15) (15) (15) (15) (15)
Hypertrophy 7 [1.1] 10 [1.4] 3 [1.3] 5 [1.2] 1 [1.0] 3 [1.3]
Myelodysplasia 2 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Adrenal Medulla (15) (15) (15) (15) (15) (15)
Infiltration Cellular 2 [2.5]
Myelodysplasia 2 [1.5]
Pituitary Gland (15) (14) (15) (15) (15) (15)
Pars Distalis, Cyst 1 [1.0] 3 [1.0]
Thyroid Gland (15) (15) (15) (15) (15) (15)
Inflammation, Chronic Active 1 [1.0]
Myelodysplasia 1 [1.0]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (15) (14) (15) (15) (15) (15)
Infiltration Cellular 5 [1.0] 5 [2.4]
Inflammation, Chronic Active 1 [1.0] 4 [1.3]
Myelodysplasia 5 [2.2]
Bilateral, Hypospermia 1 [3.0]
Unilateral, Hypospermia 1 [3.0] 1 [3.0] 2 [3.0]
Preputial Gland (1)
Duct, Ectasia 1 [2.0]
Testes (15) (15) (15) (15) (15) (15)
Cyst 2 [1.5] 1 [2.0] 1 [2.0] 1 [3.0]
Bilateral, Germinal Epithelium, Degeneration 1 [2.0]
Unilateral, Germinal Epithelium, Degeneration 1 [2.0] 1 [3.0] 2 [2.0] 1 [3.0] 4 [2.5]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (1)
Myeloid Cell, Hyperplasia 1 [3.0]
Lymph Node (14) (15) (14) (13) (15) (14)
Hyperplasia 1 [2.0]
Infiltration Cellular, Plasma Cell 1 [2.0]
Inflammation, Chronic Active 1 [3.0]
Myelodysplasia 1 [2.0]
Axillary, Hyperplasia, Lymphoid 1 [3.0]
Axillary, Infiltration Cellular 1 [3.0] 1 [2.0]
Axillary, Infiltration Cellular, Plasma Cell 1 [3.0] 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Axillary, Infiltration Cellular, Histiocyte 1 [2.0]
Inguinal, Myelodysplasia 1 [2.0]
Mediastinal, Hyperplasia 1 [2.0]
Mediastinal, Infiltration Cellular 4 [1.5] 2 [2.5]
Mediastinal, Myelodysplasia 1 [2.0]
Lymph Node, Mandibular (15) (15) (15) (15) (15) (15)
Hematopoietic Cell Proliferation 3 [1.7]
Hyperplasia 2 [2.0] 1 [2.0] 2 [2.0]
Hyperplasia, Plasma Cell 1 [3.0]
Infiltration Cellular 5 [2.0] 6 [2.0]
Infiltration Cellular, Plasma Cell 1 [2.0] 6 [2.0]
Myelodysplasia 2 [1.5]
Necrosis, Lymphoid 2 [1.5]
Lymph Node, Mesenteric (12) (15) (15) (15) (15) (14)
Hematopoietic Cell Proliferation 1 [2.0] 1 [2.0]
Infiltration Cellular 4 [1.8] 2 [2.0]
Myelodysplasia 3 [2.3]
Necrosis, Lymphoid 1 [2.0]
Spleen (15) (15) (15) (15) (15) (15)
Atrophy 1 [3.0]
Depletion Cellular 2 [2.5] 2 [2.0]
Hematopoietic Cell Proliferation 1 [2.0] 2 [2.0] 1 [2.0] 2 [2.0] 9 [2.1] 8 [2.5]
Infiltration Cellular 1 [1.0] 4 [1.8]
Myelodysplasia 4 [2.8]
Necrosis, Lymphoid 2 [2.0] 1 [2.0]
Thymus (15) (15) (15) (15) (14) (14)
Atrophy 4 [2.3] 1 [2.0] 2 [3.5] 4 [2.5] 5 [2.6]
Myelodysplasia 3 [2.0]
Thymocyte, Necrosis 2 [2.5]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (15) (15) (15) (15) (15) (15)
Dermis, Skin, Site of Application, Necrosis 1 [4.0]
Epidermis, Skin, Site of Application,
Hyperplasia 3 [1.0] 8 [1.8] 10 [1.9] 14 [2.4]
Epidermis, Skin, Site of Application, Ulcer 1 [2.0]
Skin, Site of Application, Cyst Epithelial
Inclusion 1
Skin, Site of Application, Hyperkeratosis 1 [2.0] 2 [2.0] 6 [1.0] 10 [1.8] 13 [1.5]
Skin, Site of Application, Inflammation,
Chronic Active 2 [1.0] 5 [1.2] 12 [1.3]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: SUBCHRON 26-WEEK WITH AVERAGE SEVERITY GRADES[b] Date: 07/12/02
Route: SKIN APPLICATION PENTAERYTHRITOL TRIACRYLATE (PETA) Time: 08:42:18
____________________________________________________________________________________________________________________________________
MICE:TGAC (FVB/N) HEMIZYGOUS MALE 0 MG/KG 0.75 1.5 3 MG/KG 6 MG/KG 12 MG/KG
MG/KG MG/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (15) (15) (15) (15) (15) (15)
Infiltration Cellular 1 [1.0] 3 [1.3]
Inflammation, Chronic Active 1 [1.0] 2 [1.5]
Myelodysplasia 3 [2.3]
Alveolar Epithelium, Hyperplasia 1 [2.0]
Mediastinum, Infiltration Cellular 1 [2.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (15) (15) (15) (15) (15) (15)
Hydronephrosis 1 [2.0]
Infarct 1 [3.0] 2 [3.0]
Infiltration Cellular 2 [1.5] 3 [1.3]
Inflammation, Chronic Active 1 [1.0] 4 [1.3] 4 [1.5] 3 [1.3]
Mineralization 1 [1.0]
Myelodysplasia 4 [1.8]
Nephropathy 6 [1.0] 1 [1.0]
Pigmentation 1 [1.0]
Cortex, Cyst 1 [2.0] 1 [2.0] 1 [2.0] 1 [1.0]
Renal Tubule, Dilatation 1 [2.0]
Renal Tubule, Regeneration 1 [1.0] 2 [1.0] 3 [1.7]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------